Results 181 to 190 of about 8,086 (233)

Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives. [PDF]

Curr Opin Hematol
Pan L, Zhu J.
europepmc   +1 more source

Solution behaviour of Human Serum Albumin and GLP-1variants [PDF]

, 2016
Sønderby, Pernille
core  

From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases. [PDF]

Front Immunol
Yang CW, Xia T, Tan Q, Jie LG, Lou AJ, Li XX, Maitiyaer M, Huang WH, Zheng Y, Yu SL.   +9 more
europepmc   +1 more source

Nipocalimab in the management of generalized myasthenia gravis: a new targeted therapeutic approach. [PDF]

Ann Med Surg (Lond)
Khalid M, Haider E, Khan A, Haider NU.
europepmc   +1 more source

The FcRn from gene to protein and function: comparison between species. [PDF]

Front Immunol
Ortiz-Alegría LB, Xicoténcatl-García L, Cañedo-Solares I, Rico-Torres CP, Gómez-Chávez F.   +4 more
europepmc   +1 more source

Changes in the Interaction Properties of Antibodies with Fc Receptors upon Binding to Target Antigens. [PDF]

Biosensors (Basel)
Grevtsev AS, Kommer AA, Zelmanchuk IS, Avdiushkin AS, Ermolaeva EO, Tiulin AA, Chernyshova DO, Azarian AD, Gordeev AA, Misorin AK.   +9 more
europepmc   +1 more source

Nipocalimab Dose Selection in Generalized Myasthenia Gravis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Valenzuela B, Neyens M, Zhu Y, Ramchandren S, Dosne AG, Leu JH, Faelens R, Ling LE, Pérez-Ruixo JJ.   +8 more
europepmc   +1 more source

Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report. [PDF]

BMC Neurol
Hu BQ, Wu SX, Tong QW, Ye H, Jin PP.
europepmc   +1 more source

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. [PDF]

Cancers (Basel)
Monteiro JF, Fernandes A, Tato DG, Moreira E, Ribeiro R, Reguengo H, Gonçalves J, Fresco P.   +7 more
europepmc   +1 more source